Today: 7 February 2026
Subscribe
Browse Category

NYSE:ULTY News 7 December 2025

YieldMax Ultra Option Income Strategy ETF (ULTY) Stock: 2025 Price, 77% Yield, Reverse Split and 2026 Outlook

YieldMax Ultra Option Income Strategy ETF (ULTY) Stock: 2025 Price, 77% Yield, Reverse Split and 2026 Outlook

Date: December 7, 2025Ticker: ULTY (NYSE Arca) The YieldMax Ultra Option Income Strategy ETF (ULTY) has become one of the most talked‑about high‑yield ETFs in 2025. Its headline distribution rate in the mid‑70% range, triple‑digit trailing yield figures on some data platforms, and a fresh 1‑for‑10 reverse stock split have pushed ULTY into the spotlight for income hunters and skeptics alike. Investing.com+1 Below is a comprehensive look at the latest news, distributions, performance data, analyst commentary and scenario‑based outlook as of December 7, 2025 — written in a way that’s optimized for readers searching for “ULTY stock,” “YieldMax Ultra Option
7 December 2025
··

Stock Market Today

Philip Morris stock price: PM steadies near $183 after upbeat 2026 forecast puts Zyn battle back in view

Philip Morris stock price: PM steadies near $183 after upbeat 2026 forecast puts Zyn battle back in view

7 February 2026
New York, Feb 7, 2026, 15:18 EST — Market closed. Philip Morris International shares last stood at $182.81, up 0.45% from the prior session, after the company laid out a higher 2026 profit outlook tied to its nicotine pouch business. (Reuters) That matters now because the stock has become a referendum on whether smoke-free products can keep carrying earnings while the category gets crowded. Zyn is the big swing factor, and traders are watching for any sign that volume gains are coming at the cost of pricing power. With U.S. markets shut for the weekend, the next test comes at
AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop